AGLE News and Press, Aeglea BioTherapeutics Inc. From 03/05/21

Gainers: [[SNSE]] +17.5%. [[ABCL]] +8.3%. [[AGLE]] +7.6%. [[OLED]] +5.9%. [[EOLS]] +5.4%.Losers: [[CRWD]] -7.0%. [[ARDX]] -6.9%. [[NK]] -6.6%. [[CATB]] -3.2%. [[ISEE]] -3.1%. For further details see: SNSE, AGLE, CRWD and ISEE among after-hours movers

Aeglea BioTherapeutics Appoints Sara Brownstein to Board of Directors PR Newswire AUSTIN, Texas , Feb. 24, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therape...

Aeglea BioTherapeutics (AGLE) announces that the company's chief financial officer, Charles York, will be stepping down from his role effective February 12, 2021.Aeglea has initiated a search process to identify a new chief financial officer. York is making the move to take up the role of chi...

Aeglea BioTherapeutics Announces Transition of Chief Financial Officer PR Newswire AUSTIN, Texas , Feb. 3, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeu...

Aeglea BioTherapeutics ([[AGLE]] -4.8%) disclosed updated guidance on the enrollment completion of its Phase 3 PEACE trial evaluating pegzilarginase in patients with arginase 1 deficiency (ARG1-D).Citing COVID-19 related disruptions, the company expects to complete enrollment by the end of Ma...

Aeglea BioTherapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference PR Newswire AUSTIN, Texas , Jan. 4, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enz...

Shares are trading under $10 IPO price, but the company has made significant progress with its human enzyme technology platform. Enterprise value is less than 1 times peak sales for their lead drug (in pivotal study) with data from a second more lucrative indication expected in the me...

Aeglea BioTherapeutics Appoints Alison Lawton to Board of Directors AUSTIN, Texas , Dec. 17, 2020 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovativ...

The FDA has designated has granted Rare Pediatric Disease tag to Aeglea BioTherapeutics' (AGLE) ACN00177 for the treatment of Homocystinuria, a metabolic disorder in which the body is unable to process certain building blocks of proteins (amino acids ) properly, and is ...

Aeglea BioTherapeutics Receives FDA Rare Pediatric Disease Designation for ACN00177 for the Treatment of Homocystinuria Company eligible to receive Priority Review Voucher upon FDA approval of ACN00177 PR Newswire AUSTIN, Texas, Dec. 1, 2020 AUSTIN, Texas , ...